Disclosures
Neeraj Agarwal, MD
Professor of Medicine; Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research; Co-Leader, Center of Investigational Therapeutics; Director, Genitourinary Oncology Program, Huntsman Cancer Institute, University of Utah, Salt Lake City
Served on scientific advisory board or as a consultant or expert witness for Astellas Pharma US, AstraZeneca, Aveo Pharmaceuticals, Bayer HealthCare, Bristol Myers Squibb, Calithera Eisai, Eli Lilly and Company, Exelixis, Genentech, Gilead Sciences, Immunomedics, MEI Pharma, and Merck & Co.
Jennifer R. Brown, MD, PhD
Associate Professor of Medicine, Dana-Farber Cancer Institute, Boston
Received clinical research support/data safety monitoring board from Acerta Pharma, BeiGene, Catapult, Eli Lilly and Company, Gilead Sciences, MEI Pharma, SecuraBio, and TG Therapeutics
Served on scientific advisory board or as a consultant or expert witness for AbbVie, Acerta Pharma, BeiGene, Catapult, Celgene, Genentech, Janssen Pharmaceutica Products, Juno Therapeutics, MEI Pharma, MorphoSys AG, and Novartis
Alexander Drilon, MD
Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, New York
Received honoraria and consulting fees for advisory boards from Ignyta/F. Hoffmann–La Roche/Genentech, Loxo/Bayer/Eli Lilly, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Takeda/Ariad/Millennium, Helsinn, BeiGene, BerGenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, AbbVie, 14ner/Elevation Oncology, Remedica Ltd, ArcherDX, Monopteros, Novartis, EMD Serono, Liberum, Repare RX, and Melendi
Received associated research funding paid to institution by Pfizer, Exelixis, Taiho, Teva, GlaxoSmithKline, and PharmaMar
Received research funding from Foundation Medicine; royalties from Wolters Kluwer; other from Merck, Puma, Merus, and Boehringer Ingelheim; CME honoraria from Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, and MJH Life Sciences
David S. Ettinger, MD, FACP, FCCP
Alex Grass Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Served on scientific advisory board or as a consultant or expert witness for BeyondSpring Pharmaceuticals
Thomas Flaig, MD
Professor, Medicine-Medical Oncology and Associate Dean for Clinical Research, School of Medicine, University of Colorado Cancer Center, Aurora
Received clinical research support/data safety monitoring board from Agensys, Astellas Pharma US, AstraZeneca, Bristol Myers Squibb, Genentech, Janssen, Merck & Co, sanofi-aventis U.S., and Seattle Genetics
Served on scientific advisory board or as a consultant or expert witness for Aurora Oncology, Janssen, and Seattle Genetics
Was issued patent for work done as an employee of Aurora Oncology, University of Colorado
Leo I. Gordon, MD, FACP
Abby and John Friend Professor of Cancer Research; Professor of Medicine; Co-Director, Hematologic Malignancy Program; Medical Director, John and Lillian Mathews Cellular Therapy Laboratory, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago
Received clinical research support/data safety monitoring board from Janssen Pharmaceutica Products, LP
Served on scientific advisory board or as a consultant or expert witness for Epizyme and Janssen Pharmaceutica Products, LP
William J. Gradishar, MD, FACP, FASCO
Betty Bramsen Professor of Breast Oncology and Chief, Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Received clinical research support/data safety monitoring board from Daiichi Sankyo, Genentech, Immunomedics, Novartis, and Seattle Genetics
Served on scientific advisory board or as a consultant or expert witness for AstraZeneca, Merck & Co, and Pfizer
Prashant Kapoor, MD
Assistant Professor of Medicine and Oncology (Division of Hematology), Mayo Clinic, Rochester, Minnesota
Served on scientific advisory board or as a consultant or expert witness for AbbVie, Cellectar, and Sanofi
Received research funding from AbbVie, Amgen, GlaxoSmithKline, Janssen, Karyopharm, Sanofi, and Takeda
Received honoraria from BeiGene, Janssen, Karyopharm, and Takeda
Shaji K. Kumar, MD
Professor of Medicine, Mayo Clinic, Rochester, Minnesota
Received clinical research support/data safety monitoring board from AbbVie, Allogene, Bristol Myers Squibb, Carsgen, Celgene, GlaxoSmithKline, MedImmune, Oncopeptides, Roche Laboratories, Takeda Pharmaceuticals North America, and Tenebio
Served on scientific advisory board or as a consultant or expert witness for AbbVie, BeiGene, Bluebird, Celgene, Constellation Enzyme, GlaxoSmithKline, Oncopeptides, Regeneron Pharmaceuticals, Roche Laboratories, sanofi-aventis US, Secura, and Takeda Pharmaceuticals North America
Karl D. Lewis, MD
Associate Professor, Division of Medical Oncology, University of Colorado Denver School of Medicine
Received honoraria from Incyte and Array BioPharma
Received research funding from Roche, Merck, Incyte, Array BioPharma, Nektar, Iovance Biotherapeutics, and Bristol Myers Squibb
Served as a consultant or advisor to Array BioPharma, Merck, Roche, and Regeneron Pharmaceuticals
Rebecca Olin, MD, MS
Associate Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco
Received clinical research support from or served on data safety monitoring board for Astellas Pharma US, AstraZeneca, Cellectis, Genentech, Mirati, Novartis, Pfizer, Spectrum Pharmaceuticals, and Takeda Pharmaceuticals North America
Served on scientific advisory board or as a consultant or expert witness for AbbVie, Actinium, Amgen, Astellas Pharma US, Bayer HealthCare, Blueprint Medicine, and Oncocyte
Gregory J. Riely, MD, PhD
Vice Chair, Clinical Research, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
Received institutional research support from Chugai, Eli Lilly and Company, Genentech, Merck & Co, Mirati, Novartis, Pfizer, and Takeda Pharmaceuticals North America
Served on scientific advisory board or as a consultant or expert witness to Daiichi Sankyo, Flatiron Health, Mirati, and Takeda Pharmaceuticals North America
Medical Writers:
The following medical writers reported no conflicts of interest.
Jenna Carter, PhD, Vanessa A. Carter, BS; Cordi Craig, MS; Hope Craig; Joseph Cupolo; Celeste L. Dixon; Joseph Fanelli; Julia Fiederlein; Lauren Harrison, MS; Kelly M. Hennessey, PhD; Justine Landin, PhD; Susan London; Joshua Madera, MS; Margie Miller; Anna Nowogrodzki; Susan Reckling; Kayci Reyer; Emily Rhode; Jocelyn Solis-Moreira, MS; Joshua Swore
Sarah Campen, PharmD: Her spouse works for Johnson & Johnson/Janssen.